| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $402.84B | +15.1% |
| Cost of Revenue | $162.53B | +11.1% |
| R&D Expense | $61.09B | +23.8% |
| SG&A Expense | $21.48B | +51.4% |
| Operating Income | $129.04B | +14.8% |
| Pre-tax Income | $158.83B | +32.6% |
| Income Tax | $26.66B | +35.3% |
| Net Income | $132.17B | +32.0% |
| EPS (Basic) | $10.91 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $30.71B | +30.9% |
| Short-term Investments | $96.14B | +33.2% |
| Accounts Receivable | $62.89B | +20.1% |
| Current Assets | $206.04B | +25.9% |
| Total Assets | $595.28B | +32.2% |
| Current Liabilities | $102.75B | +15.3% |
| Long-term Debt | $49.09B | +309.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $164.71B | +31.5% |
| Capital Expenditures | $91.45B | +74.1% |
| Investing Cash Flow | -$120.29B | -164.2% |
| Financing Cash Flow | -$37.39B | +53.1% |
| Free Cash Flow | $73.27B | +0.7% |
| +34.2% |
| EPS (Diluted) | $10.81 | +34.5% |
| Total Liabilities |
| $180.02B |
| +43.8% |
| Stockholders' Equity | $415.26B | +27.7% |